Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors,European Journal of Nuclear Medicine and Molecular Imaging

当前位置： X-MOL 学术 › Eur. J. Nucl. Med. Mol. Imaging › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
European Journal of Nuclear Medicine and Molecular Imaging ( IF 8.6 ) Pub Date : 2019-11-21 , DOI: 10.1007/s00259-019-04615-x
Romain-David Seban , Laura Mezquita , Arnaud Berenbaum , Laurent Dercle , Angela Botticella , Cécile Le Pechoux , Caroline Caramella , Eric Deutsch , Serena Grimaldi , Julien Adam , Samy Ammari , David Planchard , Sophie Leboulleux , Benjamin Besse

We aimed to evaluate if imaging biomarkers on FDG PET are associated with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).

中文翻译：